Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement. (May 2015)

• Record Type: Journal Article
• Authors: Choudry, Fizzah A; Yeo, Chia; Mozid, Abdul; Martin, John F; Mathur, Anthony
• Is Part Of: Regenerative medicine. Volume 10:Number 3(2015)
• Page Start: 403
• Page End: 410
• Publication Date: 2015-05
• Subjects: ischemic heart failure -- stem cell therapy -- thymosin β4; Cellular therapy -- Periodicals; Stem cells -- Transplantation -- Periodicals; Degeneration (Pathology) -- Treatment -- Periodicals; Regeneration (Biology) -- Periodicals; 611.018
• DOI: 10.2217/rme.15.9
• Languages: English
• ISSNs: 1746-0751

Abstract

Aim: Tβ4 is an integral factor in repair of myocardium in animal models. To investigate whether Tβ4 is important in human cardiac disease and has a role in mediating the beneficial cardiac effects of bone-marrow-derived stem cell (BMSC) therapy, we measured serial plasma Tβ4 levels in patients enrolled on the REGENERATE-IHD cell therapy trial.Patients & Methods: Plasma Tβ4 concentrations were measured in 13 patients who received BMSCs and 14 controls.Results: There was a significant increase in plasma Tβ4 in the BMSC group 24 h after intracardiac injection. Increases in Tβ4 levels were associated with improvement in New York Heart Association symptom class.Conclusion: This exploratory study highlights the need for further study of Tβ4 in human cardiovascular disease.